A promising new class of drugs is proving powerful in the fight against ovarian cancer. The race to create the next potent ovarian cancer drug is coming to a head. In recent days, the researchers behind three PARP drug contenders threw down preliminary data during the European Society for Medical Oncology conference in Denmark. Massachusetts-based Tesaro was the clear front-runner with its experimental once-a-day ovarian cancer pill, niraparib. Its results built upon exciting data it released in June -- showing that its drug can increase the window of time in which a woman's cancer doesn't get worse.
Oct-9-2016, 16:45:26 GMT